Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.

Participants needed: 126
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Genuine Research Center, EgyptUpdated: Sep 26, 2024
Eligibility criteria

Male or female patients aged between 18 and 65 years. [+4]

Pregnant or lactating women. [+21]

Status: Recruiting

Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension

The trial is designed to assess the safety and investigation of the efficacy of a single oral dose of bisoprolol (Nerkardou - Nerhadou) oral dissolvable film (ODF) 5 \& 10 mg, and patients' compliance in the treatment of essential hypertension. This is a Phase IV, open-label, single-arm, prospective trial where subjects will receive: 1. Bisoprolol (Nerkardou) at an initial dose of 5 (mg) milligrams once daily for 2 weeks. 2. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then the dose will be titrated to 10 mg once daily (non-responders). Dose-Titration will be done at any follow-up visit based on the response. 3. The total duration of study treatment will be 12 weeks ±2 days, and the total sample size of the study will be 406 participants.

Participants needed: 406
Trial details
Phase: Phase 4Age: 21-65Biological sex: AllType: InterventionalSponsor: Genuine Research Center, EgyptUpdated: Aug 19, 2024Locations: 1
Eligibility criteria

The participant is willing and able to give informed consent for participation i... [+9]

Grade III hypertension or malignant hypertension (Hypertensive crisis: Systolic... [+16]